Proc Natl Acad Sci U S A. 2017 Jun 5. pii: 201704065. doi: 10.1073/pnas.1704065114.
[Epub ahead of print]
Chicca A1, Nicolussi S1, Bartholomäus R2, Blunder M3,4, Aparisi Rey A5, Petrucci V1, Reynoso-Moreno IDC1,6, Viveros-Paredes JM6, Dalghi Gens M1, Lutz B5, Schiöth HB3, Soeberdt M7, Abels C7, Charles RP1, Altmann KH2, Gertsch J8.
Abstract
The extracellular effects of the endocannabinoids anandamide and 2-arachidonoyl glycerol are terminated by enzymatic hydrolysis after crossing cellular membranes by facilitated diffusion. The lack of potent and selective inhibitors for endocannabinoid transport has prevented the molecular characterization of this process, thus hindering its biochemical investigation and pharmacological exploitation. Here, we report the design, chemical synthesis, and biological profiling of natural product-derived N-substituted 2,4-dodecadienamides as a selective endocannabinoid uptake inhibitor. The highly potent (IC50 = 10 nM) inhibitor N-(3,4-dimethoxyphenyl)ethyl amide (WOBE437) exerted pronounced cannabinoid receptor-dependent anxiolytic, antiinflammatory, and analgesic effects in mice by increasing endocannabinoid levels. A tailored WOBE437-derived diazirine-containing photoaffinity probe (RX-055) irreversibly blocked membrane transport of both endocannabinoids, providing mechanistic insights into this complex process. Moreover, RX-055 exerted site-specific anxiolytic effects on in situ photoactivation in the brain. This study describes suitable inhibitors to target endocannabinoid membrane trafficking and uncovers an alternative endocannabinoid pharmacology.
KEYWORDS:
2-AG; endocannabinoid reuptake; endocannabinoid system; inhibitor; lipid transport
- PMID: 28584105
- DOI: 10.1073/pnas.1704065114
-
Conflict of interest statement
The authors declare no conflict of interest.